Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Meningeal Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Metastatic 1 Brain Neoplasms 1

Interventions

Fulvestrant 6 Letrozole 4 Capecitabine 4 exemestane 3 dalpiciclib 3 Trastuzumab 3 Docetaxel 3 Anastrozole 3 ribociclib 2 palbociclib 2 fluzoparib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Rogaratinib 1 Patient Reported Outcome Measures 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × patritumab deruxtecan × Breast × Clear all

NCT06298084 2024-03-29

ICARUSBREAST02

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡